{"id":"W2954444471","doi":"10.1016/j.clinph.2019.04.704","title":"P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial","year":2019,"lang":"en","type":"article","venue":"Clinical Neurophysiology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Multiple sclerosis; Medicine; Open label; Surgery; Randomized controlled trial; Internal medicine; Psychiatry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001723043,0.001150923,0.002381165,0.0001975895,0.0003800926,0.001068119,0.0005597365,0.001086935,0.001595563],"category_scores_gemma":[0.00153532,0.0002163063,0.001516525,0.0002847888,0.0005750346,0.0008601053,0.0003115174,0.002283776,0.00038389],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005630815,"about_ca_system_score_gemma":0.0007783289,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001053579,"about_ca_topic_score_gemma":0.002164625,"domain_scores_codex":[0.9993806,0.0002674037,0.00003939283,0.0001012102,0.00006232088,0.0001490878],"domain_scores_gemma":[0.9992189,0.0002022443,0.0002071727,0.00006925757,0.00007212294,0.0002302781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8618904,0.005233473,0.008837075,0.001152625,0.002616892,0.000271342,0.0001850198,0.0006852548,0.01116594,0.000254467,0.00300865,0.1046988],"study_design_scores_gemma":[0.6864752,0.208096,0.09405128,0.0002720765,0.002580827,0.0006206663,0.000155888,0.001041903,0.002345306,0.0006182495,0.003679356,0.0000633352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878177,0.008090518,0.0001986924,0.0005022085,0.0002073745,0.000277294,0.000609861,0.00005152771,0.002244883],"genre_scores_gemma":[0.9955824,0.001832123,0.0002536965,0.0004512578,0.0001993287,0.0002460011,0.0006571109,0.000007512824,0.0007705581],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002381165,"threshold_uncertainty_score":0.009112418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09123128346415652,"score_gpt":0.3911112634821625,"score_spread":0.299879980018006,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}